Skip to main content

Table 5 Subgroup analysis based on age (< 60/≥60 years) and gender (male/female)

From: Association of insulin resistance indicators with hepatic steatosis and fibrosis in patients with metabolic syndrome

Variables

Hepatic steatosisa

Hepatic fibrosisb

Adjusted Model

Adjusted Model

OR (95% CI)

P

OR (95% CI)

P

Age < 60 years (n = 479)

    

 HOMA-IR

    

  < 3.11

Ref

Ref

  3.11–5.81

2.08 (0.94–4.62)

0.070

3.77 (0.75–18.97)

0.100

  ≥ 5.81

3.74 (1.35–10.36)

0.015

5.31 (1.29–21.83)

0.024

 TyG

    

  < 8.90

Ref

Ref

  8.90–9.30

1.23 (0.55–2.73)

0.592

0.40 (0.16–1.05)

0.060

  ≥ 9.30

2.27 (0.94–5.50)

0.067

0.58 (0.15–2.23)

0.404

 TyG-WHtR

    

  < 5.55

Ref

Ref

  5.55–6.29

2.01 (0.94–4.31)

0.069

0.99 (0.17–5.79)

0.987

  ≥ 6.29

6.33 (3.31–12.08)

< 0.001

11.72 (2.65–51.92)

0.003

 METS-IR

    

  < 46.27

Ref

Ref

  46.27–57.04

1.37 (0.70–2.67)

0.329

4.56 (1.51–13.78)

0.010

  ≥ 57.04

5.01 (2.63–9.55)

< 0.001

16.55 (4.00–68.38)

<.001

Age ≥ 60 years (n = 397)

    

 HOMA-IR

    

  < 3.11

Ref

Ref

  3.11–5.81

3.73 (1.07–13.06)

0.041

1.46 (0.53–4.08)

0.440

  ≥ 5.81

12.30 (4.33–34.92)

< 0.001

3.36 (0.97–11.65)

0.055

 TyG

    

  < 8.90

Ref

Ref

  8.90–9.30

1.09 (0.45–2.65)

0.835

1.12 (0.31–4.05)

0.854

  ≥ 9.30

2.43 (0.86–6.92)

0.089

0.84 (0.30–2.36)

0.726

 TyG-WHtR

    

  < 5.55

Ref

Ref

  5.55–6.29

3.50 (1.59–7.72)

0.004

1.96 (0.59–6.52)

0.250

  ≥ 6.29

6.38 (2.88–14.14)

< 0.001

6.47 (2.14–19.60)

0.003

 METS-IR

    

  < 46.27

Ref

Ref

  46.27–57.04

2.20 (0.94–5.19)

0.068

0.97 (0.29–3.29)

0.958

  ≥ 57.04

9.30 (4.45–19.46)

< 0.001

3.58 (1.38–9.25)

0.012

Gender-male (n = 407)

    

 HOMA-IR

    

  < 3.11

Ref

Ref

  3.11–5.81

3.36 (1.31–8.61)

0.015

3.15 (0.95–10.41)

0.059

  ≥ 5.81

8.74 (3.15–24.19)

< 0.001

4.62 (1.75–12.23)

0.004

 TyG

    

  < 8.90

Ref

Ref

  8.90–9.30

1.14 (0.33–3.89)

0.829

0.96 (0.32–2.83)

0.930

  ≥ 9.30

1.96 (0.64–5.96)

0.218

1.00 (0.24–4.23)

0.999

 TyG-WHtR

    

  < 5.55

Ref

Ref

  5.55–6.29

2.87 (1.58–5.22)

0.002

1.47 (0.30–7.23)

0.614

  ≥ 6.29

23.36 (9.59–56.87)

< 0.001

11.14 (2.05–60.51)

0.008

 METS-IR

    

  < 46.27

Ref

Ref

  46.27–57.04

2.41 (0.84–6.89)

0.095

0.51 (0.20–1.34)

0.159

  ≥ 57.04

11.42 (3.87–33.70)

< 0.001

4.47 (1.49–13.41)

0.011

Gender-female (n = 469)

    

 HOMA-IR

    

  < 3.11

Ref

Ref

  3.11–5.81

1.97 (0.91–4.25)

0.079

2.89 (0.57–14.69)

0.185

   ≥ 5.81

3.61 (1.56–8.36)

0.005

4.92 (1.18–20.45)

0.031

 TyG

    

  < 8.90

Ref

Ref

  8.90–9.30

1.22 (0.59–2.54)

0.568

0.41 (0.15–1.12)

0.077

  ≥ 9.30

2.94 (1.54–5.62)

0.003

0.60 (0.16–2.20)

0.415

 TyG-WHtR

    

  < 5.55

Ref

Ref

  5.55–6.29

2.09 (0.94–4.64)

0.068

1.31 (0.24–7.03)

0.737

  ≥ 6.29

4.88 (2.33–10.21)

< 0.001

8.78 (2.02–38.27)

0.007

 METS-IR

    

  < 46.27

Ref

Ref

  46.27–57.04

0.94 (0.42–2.15)

0.885

3.40 (1.20–9.58)

0.024

  ≥ 57.04

3.82 (2.12–6.90)

< 0.001

7.96 (2.27–27.91)

0.003

  1. METS-IR metabolic score for insulin resistance, TyG triglyceride/glucose, HOMA-IR homeostasis model assessment of IR, TyG-WHtR triglyceride glucose-waist-to-height ratio, OR odds ratio, CI confidence interval
  2. Crude model: confounding variables were not adjusted
  3. aAdjusted Model: education level, hepatitis, cardiovascular disease (CVD), alanine aminotransferase (ALT), drug for hypertension, and protein were adjusted
  4. bAdjusted Model: family income-to-poverty ratio, diastolic blood pressure, CVD, ALT, aspartate aminotransferase, gamma glutamyl transferase, platelet count, albumin, drug for diabetes, antiviral agents, and hepatic steatosis were adjusted
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us